Cavo M - Search Results

1

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.

Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Among authors: cavo m. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Clinical Trial.

2

Allogeneic bone marrow transplantation in multiple myeloma.

Tura S, Cavo M. Tura S, et al. Among authors: cavo m. Hematol Oncol Clin North Am. 1992 Apr;6(2):425-35. Hematol Oncol Clin North Am. 1992. PMID: 1582983 Review.

3

Accelerated hemopoietic recovery after chemotherapy and autologous bone marrow transplantation in hematological malignancies using recombinant GM-CSF: preliminary results obtained in 14 cases.

Visani G, Tosi P, Gamberi B, Cenacchi A, Mazzanti P, Stabilini C, Bandini G, Mazza P, Gherlinzoni F, Cavo M, et al. Visani G, et al. Among authors: cavo m. Haematologica. 1990 Nov-Dec;75(6):551-4. Haematologica. 1990. PMID: 2098298

4

Normal myeloid progenitors (CFU-GM) in multiple myeloma: a preliminary study in view of autologous BMT.

Lemoli RM, Visani G, Gobbi M, Rizzi S, Dinota A, Tassi C, Tosi P, Galieni P, Cavo M, Tura S. Lemoli RM, et al. Among authors: cavo m. Bone Marrow Transplant. 1989 Jul;4(4):373-7. Bone Marrow Transplant. 1989. PMID: 2673456

5

Allogeneic bone marrow transplantation for multiple myeloma.

Tura S, Cavo M, Rosti G, Bandini G, Gobbi M, Grimaldi M, Miggiano MC, Albertazzi L, Bonelli MA. Tura S, et al. Among authors: cavo m. Bone Marrow Transplant. 1989 Dec;4 Suppl 4:106-8. Bone Marrow Transplant. 1989. PMID: 2697418 Clinical Trial.

6

M-2 protocol for melphalan-resistant and relapsing multiple myeloma.

Cavo M, Galieni P, Tassi C, Gobbi M, Tura S. Cavo M, et al. Eur J Haematol. 1988 Feb;40(2):168-73. doi: 10.1111/j.1600-0609.1988.tb00816.x. Eur J Haematol. 1988. PMID: 3345830

7

Expression and functional role of c-kit ligand (SCF) in human multiple myeloma cells.

Lemoli RM, Fortuna A, Grande A, Gamberi B, Bonsi L, Fogli M, Amabile M, Cavo M, Ferrari S, Tura S. Lemoli RM, et al. Among authors: cavo m. Br J Haematol. 1994 Dec;88(4):760-9. doi: 10.1111/j.1365-2141.1994.tb05115.x. Br J Haematol. 1994. PMID: 7529540

8

Allogeneic bone marrow transplantation for the treatment of multiple myeloma. An overview of published reports.

Cavo M, Benni M, Cirio TM, Gozzetti A, Tura S. Cavo M, et al. Stem Cells. 1995 Aug;13 Suppl 2:126-31. doi: 10.1002/stem.5530130720. Stem Cells. 1995. PMID: 8520501 Review.

9

High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma.

Cavo M, Bandini G, Benni M, Gozzetti A, Ronconi S, Rosti G, Zamagni E, Lemoli RM, Bonini A, Belardinelli A, Motta MR, Rizzi S, Tura S. Cavo M, et al. Bone Marrow Transplant. 1998 Jul;22(1):27-32. doi: 10.1038/sj.bmt.1701280. Bone Marrow Transplant. 1998. PMID: 9678792

10

In vitro treatment with retinoids decreases bcl-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells.

Tosi P, Pellacani A, Visani G, Ottaviani E, Ronconi S, Zamagni E, Benni M, Cavo M, Tura S. Tosi P, et al. Among authors: cavo m. Eur J Haematol. 1999 Mar;62(3):143-8. doi: 10.1111/j.1600-0609.1999.tb01736.x. Eur J Haematol. 1999. PMID: 10089890

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

612 results

Search Page